Disclaimer

This service is solely for personal and non-commercial use and general information and reference only. This information is strictly prohibited for distributing or made available to any person. The information in this website relating to funds is provided by Morningstar Asia Limited (“Information Provider”) to Chief Securities Limited (the "Company") unless otherwise specified. For technical reasons, certain information provided by Information Provider may be different from that supplied by the respective fund houses. Neither the Information Provider nor the Company guarantee or endorse the accuracy, reliability and completeness of the information provided by the Information Provider or that it is up-to-date, and that such information has not been independently verified by the Company. The Company disclaims liability for any errors, omissions, or inaccuracies in the information provided in this website. The Company also disclaims liability for any loss or damages resulting from the use of the information contained herein, or the inability to use such information or in connection with any error, interruption, delay in operation or incomplete transmission, line or system failure.

For information which is "Powered By" the Information Provider and other fund houses, it is being re-transmitted by the Company in the ordinary course of business to you for general information and reference purposes only.

This service should not be regarded as an offer, solicitation, or recommendation to buy or sell investment products in any jurisdiction to any person to whom it is unlawful to make such an invitation, offer, solicitation or recommendation in such jurisdictions.

The relevant pages for funds have not been reviewed by the Securities and Futures Commission in Hong Kong ("SFC"). The information contained herein is for general information and reference purposes only and is not intended to provide professional investment or other advice. It is not intended to form the basis of any investment decision. Persons accessing this website should not make any investment decision based solely on the information and services provided herein. Before making any investment decision, persons accessing this website should take into account his/her own circumstances including but not limited to his/her financial situation, investment experience, and investment objectives, and should understand the nature, terms and risks of the relevant funds. Persons accessing these pages should obtain appropriate professional advice where necessary.

Investors should note that all investments involve risks (including the possibility of a loss of the capital invested), prices of funds may go up as well as down and past performance information presented is not necessarily a guide to the future performance. Investors should read the relevant fund’s offering documents (including the stated full text of the risk factors) and seek independent financial advice before making any investment decision. Smaller or emerging markets for funds can be more volatile than developed markets and can carry more risk. Independent financial advice should be taken before entering into any financial transaction. The information, contents and/ or features of the webpages are subject to change without notice.

Disclaimer
Important message to readers and internet privacy policy statement
Copyright © 2024 Chief Group Limited. All rights reserved.

Provide Chinese Only.

最新文章

疫苗研發成功在即 經濟復甦加快有望

2020年11月11日

疫苗曙光令全球經濟復甦在望,但市場仍然擔心疫苗之生產進度。美國拜登亦表示大規模接種疫苗仍需數月時間,故群眾仍需注重防疫措施及保持社交距離。不過,投資者憧憬疫苗有助恢復經濟活動,消費、旅遊等行業受惠,舊經濟股受到追捧。

上星期報導美國聯儲局主席鮑威爾對新冠肺炎疫情升溫的情況表示擔憂,在民眾感到安全之前,美國經濟不可能實現全面復甦。11月9日星期一傍晚 (香港時間),美國藥廠輝瑞公布新冠疫苗三期臨床試驗首次中期療效分析結果令歐美股市飆升。

疫苗曙光令全球經濟復甦在望,但市場仍然擔心疫苗之生產進度。美國拜登亦表示大規模接種疫苗仍需數月時間,故群眾仍需注重防疫措施及保持社交距離。不過,投資者憧憬疫苗有助恢復經濟活動,消費、旅遊等行業受惠,舊經濟股受到追捧。

美國聯儲局周發表半年度金融穩定報告的內容,其中提及如果疫情持續時間比預期要長,特別是如果研制成功的疫苗在生產或分發上時間延後,將對美國經濟產生下行壓力,使經濟脫離剛剛踏上的復甦軌道,並給金融市場造成壓力。當全球正等候有效疫苗推出的同時,亦期待美國推出新一輪之經濟刺激方案,但總統大選結果出現爭拗,或會阻礙方案通過進度。

有效疫苗的消息,為全球經濟復甦帶來希望,但同時亦增添股市波動,不同板塊股票個別發展。其實,亞洲區內整體對疫情控制一直做得不錯, 倘日後加上疫苗之應用,有助進一步深化區內經濟活動。

由即日起到12月31日,用致富通「零」活投資基金, 認購費低至 $0*,認購金額更低至港幣 $5,000或700美元*, 而且部份基金仲有每月派息功能,月月收息。

詳情 :推廣資訊

致富有提供債券、基金一站式投資策略,比供客戶選擇。想知道和了解更多,請即刻聯絡我哋們投資策略專員解答疑難!

WhatsApp : 投資策略專員

更多基金資訊、種類 和 比較:

連結

投資涉及風險,以上建議只作為參考之用。致富在法律上均不負責任何人因使用本報告內資料而蒙受的任何直接或間接損失。以上報告由致富集團研究部的分析員(“此等人士”)所撰寫,此等人士均為香港證監會持牌人士。此外,截至本報告發表當日,此等人士均未於本報告中所推介的股份存有權益。



免責聲明
上述報告由致富證券有限公司(「本公司」)所提供,所載之內容或意見乃根據本公司認為可靠之資料來源來編製,惟本公司並不就此等內容之準確性、完整性及正確性作出明示或默示之保證。上述報告內之所有意見均可在不作另行通知之下作出更改。上述報告的作用純粹為提供資訊,並不應視為對上述報告內提及的任何產品買賣或交易之專業推介、建議、邀請或要約。本公司及其附屬公司、僱員及其家屬及有關人士可於任何時間持有、買賣或以市場認可之方式,包括以代理人或當事人對本報告內提及的任何產品進行投資或買賣。投資附帶風險,投資者需注意投資項目之價值可升亦可跌,而過往之表現亦不一定反映未來之表現。投資者進行投資前請尋求獨立之投資意見。本公司在法律上均不負責任何人因使用本報告內資料而蒙受的任何直接或間接損失。本公司擁有此報告內容之版權,在未獲本公司許可前,不得翻印、分發或發行本報告以作任何用途。

< 返回致富研究
App Download
Instant trading of stocks after taking an in-depth look at every move of the market
Website Push Notifications
Provide the latest financial news and promotions

Subscribe to keep up to date with CHIEF
Informative contents include:
Latest news, coming seminar, featured articles on wealth management